SequelSEC

Invivyd, Inc. IVVD

Biological Products, (No Diagnostic Substances) · CIK 0001832038 · Fiscal year ends 1231

Revenue
$58.36M
Fiscal year ended 2026-06-30
Operating income
-$112.53M
Fiscal year ended 2026-06-30
Free cash flow
-$109.66M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$50.90MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$0.18Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue1.0×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity0.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Biological Products, (No Diagnostic Substances) filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
CapEx / revenue0.3%8th
Revenue YoY growth110.5%83th
R&D / revenue71.7%29th
Operating margin-104.0%68th
Current ratio7.24x68th
Net margin-98.2%67th
SBC / revenue21.8%35th
FCF margin-109.1%60th

Invivyd, Inc. (IVVD) reported revenue of $58.36M and net income of -$107.33M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Invivyd, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

Invivyd, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$58.36M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$112.53M
Net income-$107.33M
Research & development$78.19M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expense$0
Diluted EPSUnavailable
Selling, general & administrative$88.17M
General & administrativeUnavailable
Selling & marketingUnavailable

Balance

Invivyd, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$160.08M
Total assets$218.88M
Current assets$182.11M
Total liabilities$37.80M
Current liabilities$31.03M
Total equity incl. NCI$181.08M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$11.22M
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$9.49M

Cash flow

Invivyd, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$108.42M
Capital expenditures$1.24M
Investing cash flow-$1.24M
Financing cash flow$234.83M
Net change in cash$125.18M
Stock-based compensation$11.23M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Invivyd, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$109.66M
Gross marginUnavailable
Operating margin-192.8%
FCF margin-187.9%
SBC / revenue19.2%
Current ratio5.87x
Revenue YoY growth26.3%
Net margin-183.9%
R&D / revenue134.0%
CapEx / revenue2.1%
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IVVD in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.